ProCE Banner Activity

CME

Video Module: Biomarkers of Response to Immune Checkpoint Inhibitor Therapy in Colorectal Cancer

Multimedia
In this video module, watch our distinguished faculty discuss how oncologists and pathologists can leverage established and emerging biomarkers to guide immunotherapy selection in advanced colorectal cancer.

Physicians : maximum of 1.25 AMA PRA Category 1 {Credits}

Released: August 18, 2017

Expiration: August 17, 2018

No longer available for credit.

Share

Faculty

Feriyl Bhaijee

Feriyl Bhaijee, MD

Staff Pathologist
Ameripath Indiana
Indianapolis, Indiana

E. Scott Kopetz

E. Scott Kopetz, MD, PhD, FACP

Assistant Professor
Department of Gastrointestinal Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Dipen Maru

Dipen Maru, MD

Professor
Department of Pathology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Bristol Myers Squibb

Target Audience

This program is intended for oncologists and pathologists as well as other healthcare providers who care for patients with colorectal cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Screen patients with advanced colorectal cancer for mismatch repair deficiencies, including microsatellite instability
  • Use available biomarkers of response to identify patients with colorectal cancer who may benefit from immune checkpoint inhibitor therapy
  • Evaluate the therapeutic impact of immune checkpoint inhibitors in patients with colorectal cancer
  • Plan treatment strategies for patients with MSI-H colorectal cancer based on available data, treatment guidelines, and expert recommendations

Faculty Disclosure

Primary Author

Feriyl Bhaijee, MD

Staff Pathologist
Ameripath Indiana
Indianapolis, Indiana

Feriyl Bhaijee, MD, has no real or apparent conflicts of interest to report.

E. Scott Kopetz, MD, PhD, FACP

Assistant Professor
Department of Gastrointestinal Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Scott Kopetz, MD, PhD, FACP, has disclosed that he holds intellectual property rights with Amgen, Array, Bayer, Genentech, and Taiho and has ownership interest in MolecularMatch.

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees, fees for non-CME/CE services, and funds for research support from Amgen, Caris, Celgene, Genentech, and Taiho.

Dipen Maru, MD

Professor
Department of Pathology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dipen Maru, MD, has no real or apparent conflicts of interest to report.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 18, 2017, through August 17, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of oncologists and pathologists on the latest science, on-going clinical trials, and new treatment paradigms for treating MMR-deficient/MSI-high CRC with immune checkpoint inhibitors.